PORTAL HYPERTENSION

حجازى. مصطفى د

Practice Essentials

The most common cause of portal hypertension is cirrhosis.

Vascular resistance and blood flow are 2 important factors in its development.

Signs and symptoms

Weakness, tiredness, and malaise Anorexia, weight loss (common with acute

and chronic liver disease) Sudden and massive bleeding, with or without

shock on presentation Nausea and vomiting; abdominal discomfort

and pain Jaundice or dark urine

Signs and symptoms

Edema and abdominal swelling (ascites); splenomegaly

Spider angiomas Males: Gynecomastia, testicular atrophy

(common with cirrhosis) Pruritus: Usually associated with cholestatic

conditions Spontaneous bleeding and easy bruising

Signs and symptoms

Symptoms of encephalopathy: Sleep-wake cycle disturbance; intellectual function deterioration, memory loss, and an inability to communicate effectively at any level; personality changes; and, possibly, displays of inappropriate or bizarre behavior

Impotence and sexual dysfunction Muscle cramps (common in patients with

cirrhosis), muscle wasting

Signs and symptoms

Dupuytren contracture Palmar erythema and leukonychia: May be

present in patients with cirrhosis Asterixis ("flapping tremor," "liver flap")

Complications of portal hypertension

Hematemesis or melena: May indicate gastroesophageal variceal bleeding or bleeding from portal gastropathy

Mental status changes: May indicate the presence of portosystemic encephalopathy

Increasing abdominal girth: May indicate ascites formation

Complications of portal hypertension

Abdominal pain and fever: May indicate spontaneous bacterial peritonitis, although this disease also presents without symptoms

Hematochezia: May indicate bleeding from portal colopathy

Signs of portosystemic collateral formation

Anterior abdominal wall dilated veins: May indicate umbilical epigastric vein shunts

Venous pattern on the flanks: May indicate portal-parietal peritoneal shunting

Caput medusae (tortuous paraumbilical collateral veins)

Signs of portosystemic collateral formation

Rectal hemorrhoids Ascites Paraumbilical hernia

Signs of a hyperdynamic circulatory state

Bounding pulses Warm, well-perfused extremities Arterial hypotension Flow murmur over the pericardium

Other signs of portal hypertension and esophageal varices

Pallor: May suggest active internal bleeding Parotid enlargement: May be related to

alcohol abuse and/or malnutrition Cyanosis of the tongue, lips, and peripheries:

Due to low oxygen saturation Dyspnea and tachypnea Telangiectasis of the skin, lips, and digits

Other signs of portal hypertension and esophageal varices

Fetor hepaticus: Occurs in portosystemic encephalopathy of any cause (eg, cirrhosis)

Small-sized liver Venous hums: Continuous noises audible in

patients with portal hypertension; may be present as a result of rapid, turbulent flow in collateral veins

Other signs of portal hypertension and esophageal varices

Tarry stool (digital rectal examination): Suggests upper gastrointestinal (GI) bleeding

Hemorrhoids

DiagnosisLaboratory testing

Complete blood count Liver function tests (eg, aspartate

aminotransferase [AST], alanine aminotransferase [ALT], bilirubin, alkaline phosphatase [ALP])

Type and cross-match Coagulation studies (prothrombin time [PT],

partial thromboplastin time [PTT], international normalized ratio [INR])

DiagnosisLaboratory testing

Blood urea nitrogen, creatinine, and electrolytes

Arterial blood gas (ABG) and pH measurements

Hepatic and viral hepatitis serologies, particularly hepatitis B and C serologies

Other laboratory tests

Albumin levels: Hypoalbuminemia is common (impaired hepatic synthetic function)

Antinuclear antibody, antimitochondrial antibody, antismooth muscle antibody

Iron indices

Other laboratory tests

Alpha1-antitrypsin deficiency Ceruloplasmin, 24-hour urinary copper:

Consider this test only in individuals aged 3-40 years who have unexplained hepatic, neurologic, or psychiatric disease

Imaging studies

Duplex Doppler ultrasonography of the liver and upper abdomen

Computed tomography (CT) scanning and/or magnetic resonance imaging (MRI): Can be used when ultrasonographic findings are inconclusive

Bleeding scan or angiography: Used when bleeding is obscure and the source is unclear

Procedures

Liver biopsy and histologic examination Hemodynamic measurement of the hepatic

venous pressure gradient (HVPG): A criterion standard for assessment of portal hypertension

Upper GI endoscopy (or, esophagogastroduodenoscopy [EGD]): A criterion standard for assessment of portal hypertension

Management

Treatment is directed at the cause of portal hypertension.

Gastroesophageal variceal hemorrhage is the most dramatic and lethal complication of portal hypertension; therefore, the focus is on the treatment of variceal hemorrhage.

Management of patients with liver cirrhosis and ascites but without hemorrhage includes a low-sodium diet and diuretics.

Emergent treatment

Airway, breathing, and circulation evaluation Nasogastric tube placement with

hemodynamically significant upper GI bleeding

Nothing by mouth; establish 2 large-bore venous accesses

Emergent treatment

Volume resuscitation, with or without blood product transfusion

Portal pressure reduction (ie, anti-secretory agent infusion)

Patient transfer to tertiary center with liver transplant service for uncontrolled bleeding from portal hypertension

Control and prevention of bleeding from esophageal varices

Emergent treatment

Prevention of complications (eg, prophylactic antibiotics, combination endoscopic/pharmacologic therapy)

Administration of vasoconstrictors (eg, octreotide [agent of choice in acute variceal bleeding], vasopressin)

Endoscopic therapy (variceal ligation [EVL] [preferred], injection sclerotherapy)

Balloon-tube tamponade

Emergent treatment

Percutaneous transhepatic embolization (PTE) Endoscopic administration of cyanoacrylate

monomer Transjugular intrahepatic portosystemic shunt

(TIPS)

Primary prophylaxis

Surveillance Nonselective beta-blockers (eg, propranolol,

nadolol) Vasodilators (eg, isosorbide mononitrate

[ISMN]) Combination pharmacotherapy when a single

agent fails

Secondary prophylaxis

Nonselective beta-blockers Endoscopic therapy (EVL, treatment of choice;

endoscopic sclerotherapy) Combination EVL and pharmacotherapy

Surgery

Surgery has no role in primary prophylaxis. Consider procedures, such as the following, for the prevention of rebleeding when pharmacologic and/or endoscopic therapy have failed:

Portosystemic shunts Devascularization procedures Orthotopic liver transplantation: Treatment of

choice for advanced liver disease

BackgroundMany conditions are associated with portal hypertension, with cirrhosis being the most common cause of this disorder.Two important factors—vascular resistance and blood flow—exist in the development of portal hypertension. Ohm law is V = IR, where V is voltage, I is current, and R is resistance. This can be applied to vascular flow; ie, P = FR, where P is the pressure gradient through the portal venous system, F is the volume of blood flowing through the system, and R is the resistance to flow. Changes in either F or R affect the pressure, although in most types of portal hypertension, both of these are altered.

Normal portal pressure is generally considered to be between 5 and 10 mm Hg. Once the portal pressure rises to 12 mm Hg or greater, complications can arise, such as varices and ascites. Indeed, esophageal varices are responsible for the main complication of portal hypertension, massive upper gastrointestinal (GI) hemorrhage .

PathogenesisThe portal vein carries approximately 1500 mL/min of blood from the small and large bowel, the spleen, and the stomach to the liver.

Obstruction of portal venous flow, whatever the etiology, results in a rise in portal venous pressure. The response to increased venous pressure is the development of collateral circulation that diverts the obstructed blood flow to the systemic veins. These portosystemic collaterals form by the opening and dilatation of preexisting vascular channels connecting the portal venous system and the superior and inferior vena cava.

Although high portal pressure is the main cause of the development of portosystemic collaterals, other factors, such as active angiogenesis, may also be involved. The most important portosystemic anastomoses are the gastroesophageal collaterals, which include esophageal varices. The gastroesophageal collaterals drain into the azygos vein.

The portal vein drains blood from the small and large intestines, stomach, spleen, pancreas, and gallbladder. The superior mesenteric vein and the splenic vein unite behind the neck of the pancreas to form the portal vein.

The portal trunk divides into 2 lobar veins. The right branch drains the cystic vein, and the left branch receives the umbilical and paraumbilical veins that enlarge to form umbilical varices in portal hypertension. The coronary vein, which runs along the lesser curvature of the stomach, receives distal esophageal veins, which also enlarge in portal hypertension.

Portal vein and associated anatomy

Etiology and PathophysiologyIncrease in vascular resistance The initial factor in the etiology of portal hypertension is the increase in vascular resistance to the portal blood flow. Poiseuille’s law, which can be applied to portal vascular resistance, R, states that R = 8hL/pr4, where h is the viscosity of blood, L is the length of the blood vessel, and r is the radius of the blood vessel. The viscosity of the blood is related to the hematocrit. The lengths of the blood vessels in the portal vasculature are relatively constant.

Thus, changes in portal vascular resistance are determined primarily by blood vessel radius.Because portal vascular resistance is indirectly proportional to the fourth power of the vessel radius, small decreases in the vessel radius cause large increases in portal vascular resistance and, therefore, in portal blood pressure (P = F8hL/pr4, where P is portal pressure and F is portal blood flow). Liver disease that decreases the portal vascular radius produces a dramatic increase in portal vascular resistance. In cirrhosis, the increase occurs at the hepatic microcirculation (sinusoidal portal hypertension).

Increased hepatic vascular resistance in cirrhosis is not only a mechanical consequence of the hepatic architectural disorder; a dynamic component also exists due to the active contraction of myofibroblasts, activated stellate cells, and vascular smooth-muscle cells of the intrahepatic veins. Endogenous factors and pharmacologic agents that modify the dynamic component include those that increase or decrease hepatic vascular resistance.

Factors that increase hepatic vascular resistance include endothelin-1 (ET-1), alpha-adrenergic stimulus, and angiotensin II. Factors that decrease hepatic vascular resistance include nitric oxide (NO),[6] prostacyclin, and vasodilating drugs (eg, organic nitrates, adrenolytics, calcium channel blockers).

Endothelin and nitric oxideStudies have demonstrated the role of ET-1 and NO in the pathogenesis of portal hypertension and esophageal varices. ET-1 is a powerful vasoconstrictor synthesized by sinusoidal endothelial cells that has been implicated in the increased hepatic vascular resistance of cirrhosis and in the development of liver fibrosis. NO is a vasodilator substance that is also synthesized by sinusoidal endothelial cells. In the cirrhotic liver, the production of NO is decreased, and endothelial nitric oxide synthase (eNOS) activity and nitrite production by sinusoidal endothelial cells are reduced.As a result, intrahepatic vasoconstriction occurs in cirrhotic liver and accounts for approximately 20-30% of the increased intrahepatic resistance. Another major contribution to increased portal venous pressure is the concomitant splanchnic arteriolar vasodilation causing increased portal venous inflow.

Location of resistance in relation to the liver and sinusoidsObstruction and increased resistance can occur at 3 levels in relation to the hepatic sinusoids, as follows (see the Table, below):

● Presinusoidal venous block (eg, portal vein thrombosis, schistosomiasis, primary biliary cirrhosis) - Characterized by elevated portal venous pressure and a normal wedged hepatic venous pressure (WHVP); these abnormalities cannot be detected by surrogate measurement (WHPV, HVPG), because the measured pressure represents portal pressure in the segment distal to the lesions, which is normal; however, direct measurement of the portal venous pressure will be elevated

● Postsinusoidal obstruction (eg, right sided heart failure, inferior vena caval obstruction) - WHVP is characteristically elevated, whereas the HVPG and FHVP can be either elevated or normal, depending on the site of obstruction (intrahepatic postsinusoidal vs posthepatic obstruction)●Sinusoidal obstruction (eg, cirrhosis) - Characterized by HVPG, FHVP, and WHVP, with WHVP being equal to portal venous pressure (because disrupted intersinusoidal communications diminishes compressibility and compliance of the sinusoids, allowing direct transmission of portal pressure to the WHVP)

Etiology of Portal Hypertension

WHVP FHVP HVPG

Prehepatic Normal Normal NormalIntrahepatic Presinusoid

alNormal Normal Normal

Sinusoidal Increased Increased IncreasedPostsinusoidal

Increased Normal Increased

Posthepatic Budd-Chiari syndrome

N/A Hepatic vein cannot be cannulated

N/A

Other posthepatic causes

Increased Increased Normal

FHVP = free hepatic venous pressure; HVPG = hepatic venous pressure gradient; N/A = not applicable; WHVP = wedged hepatic venous pressure.

Table 1. Interpretation of Surrogate Portal Venous Pressure

Measurements in the Differential Diagnosis of Portal Hypertension

With regard to the liver itself, causes of portal hypertension usually are classified as prehepatic, intrahepatic, and posthepat

Prehepatic resistancePrehepatic causes of increased resistance to flow include the following:•Portal vein thrombosis•Splenic vein thrombosis•Congenital atresia or stenosis of portal vein•Extrinsic compression (tumors)•Splanchnic arteriovenous fistula

Intrahepatic resistanceStudies of hepatic microcirculation have identified several mechanisms that may explain increased intrahepatic vascular resistance to flow. These mechanisms may be summarized as follows :•A reduction of sinusoidal caliber due to hepatocyte enlargementAn alteration in the elastic properties of the sinusoidal wall due to collagen deposition in the space of Disse

• Compression of hepatic venules by regeneration nodules• Central vein lesions caused by perivenous fibrosis• Veno-occlusive changes• Perisinusoidal block by portal inflammation, portal fibrosis, and piecemeal necrosis

More specifically, intrahepatic, predominantly presinusoidal causes of resistance to flow include the following:• Schistosomiasis (early stage)• Primary biliary cirrhosis (early stage)• Idiopathic portal hypertension (early stage)• Nodular regenerative hyperplasia - The pathogenesis probably is obliterative venopathy; the presence of nodules that press on the portal system has also been postulated to play a role, although nodularity is present in most cases without clinical evidence of portal hypertension

• Myeloproliferative diseases - These act via direct infiltration by malignant cells• Polycystic disease• Hepatic metastasis• Granulomatous diseases (sarcoidosis, tuberculosis) - Clinical liver dysfunction is rare in sarcoidosis, whereas portal hypertension is an unusual, although well-recognized, manifestation of hepatic sarcoidosis; sarcoid granulomas frequently localize in the portal areas, resulting in injury to the portal veins

Intrahepatic, predominantly sinusoidal causes of resistance include the following:• Hepatic cirrhosis• Acute alcoholic hepatitis• Schistosomiasis (advanced stage)• Primary biliary cirrhosis (advanced stage)• Idiopathic portal hypertension (advanced stage)• Acute and fulminant hepatitis• Congenital hepatic fibrosis• Peliosis hepatitis• Veno-occlusive disease• Budd-Chiari syndrome

• Vitamin A toxicity• Sclerosing cholangitis• Hepatitis B virus–related and hepatitis C virus–related cirrhosis• Wilson disease• Hemochromatosis• Alpha-1 antitrypsin deficiency• Chronic active hepatitis

With regard to chronic active hepatitis, noncirrhotic portal fibrosis is observed with various toxic injuries, and one of these includes vitamin A toxicity. This probably is due to vascular injury. Excessive doses of vitamin A taken for months or years can lead to chronic hepatic disease. Intake of doses ranging from as small as 3-fold the recommended daily dose continued for years to doses as high as 20-fold the approved dose for a few months can lead to hepatic disease. The pericellular fibrotic characteristic of vitamin A toxicity may lead to portal hypertension. Postsinusoidal obstruction syndrome and veno-occlusive disease of the liver are postsinusoidal causes of resistance

Posthepatic resistancePosthepatic causes of resistance to flow include the following:• Thrombosis of the inferior vena cava (IVC)• Right-sided heart failure• Constrictive pericarditis• Severe tricuspid regurgitation• Budd-Chiari syndrome• Arterial-portal venous fistula• Increased portal blood flow• Increased splenic flow

Increase in portal blood flowThe second factor that contributes to the pathogenesis of portal hypertension is an increase in blood flow in the portal veins. This increase is established through splanchnic arteriolar vasodilatation caused by an excessive release of endogenous vasodilators (eg, endothelial, neural, humoral).The increase in portal blood flow aggravates the increase in portal pressure; the increased flow contributes to the ability of portal hypertension to exist despite the formation of an extensive network of portosystemic collaterals that may divert as much as 80% of the portal blood flow.

Manifestations of splanchnic vasodilatation include increased cardiac output, arterial hypotension, and hypervolemia. This explains the rationale for treating portal hypertension with a low-sodium diet and diuretics to attenuate the hyperkinetic state.

Formation of varicesAn elevated pressure difference between systemic and portal circulation (ie, HVPG) directly contributes to the development of varices.HVPG is a surrogate marker of portal pressure gradient and is derived from WHVP corrected (subtracted) with free hepatic venous pressure (FHVP).The hypertensive portal vein is decompressed by diverting up to 90% of the portal flow through portasystemic collaterals back to the heart, resulting in enlargement of these vessels. These vessels are commonly located at the gastroesophageal junction, where they lie subjacent to the mucosa and present as gastric and esophageal varices.

Varices form when the HVPG exceeds 10 mm Hg; they usually do not bleed unless the HVPG exceeds 12 mm Hg (normal HVPG: 1-5 mm Hg). Gastroesophageal varices have 2 main inflows. The first is the left gastric or coronary vein, and the second is the splenic hilum, through the short gastric veins. The gastroesophageal varices are important because of their propensity to bleed.

Normal venous flow through the portal and systemic circulation. IMC = inferior mesenteric vein; IVC = inferior vena cava; SVC = superior vena cav

Redirection of flow through the left gastric vein secondary to portal hypertension or portal venous occlusion. Uphill varices develop in the distal one third of the esophagus. IMC = inferior mesenteric vein; IVC = inferior vena cava; SVC = superior vena cava.

Mechanisms of variceal hemorrhage

Increased portal pressure contributes to increased varix size and decreased varix wall thickness, thus leading to increased variceal wall tension. Rupture occurs when the wall tension exceeds the elastic limits of the variceal wall. Varices are most superficial at the gastroesophageal junction and have the thinnest wall in that region; thus, variceal hemorrhage invariably occurs in that area

The following are risk factors for variceal hemorrhage :Variceal size - The larger the varix, the higher the risk of rupture and bleeding; however, patients may bleed from small varices tooThe presence of endoscopic red color signs (eg, red wale markings, cherry red spots)Child B or C classification, especially the presence of ascites, increases the risk of hemorrhageActive alcohol intake in patients with chronic, alcohol-related liver diseasesLocal changes in the distal esophagus (eg, gastroesophageal reflux) – These have been postulated to increase the risk of variceal hemorrhage, but evidence to support this view is weak; studies indicate that gastroesophageal reflux does not initiate or play a role in esophageal hemorrhage.

Bacterial infection - A well-documented association exists between variceal hemorrhage and bacterial infections, and this may represent a causal relationship

Note that bacterial infection could also trigger variceal bleeding through a number of mechanisms, including the following:• The release of endotoxin into the systemic circulation• Worsening of hemostasis• Vasoconstriction induced by the contraction of stellate cells

Epidemiology

Population-based prevalence data for portal hypertension in the United States are not available, but portal hypertension is a frequent manifestation of liver cirrhosis.

According to the National Institute on Alcohol Abuse and Alcoholism (NIAAA), liver cirrhosis accounted for almost 30,000 deaths in the United States in 2007, making it the 12th leading cause of US deaths.

Epidemiology

The international incidence of portal hypertension is also not known, although it is probably similar to that of the US, with differences primarily in the causes. In Western countries, alcoholic and viral cirrhosis are the leading causes of portal hypertension and esophageal varices; 30% of patients with compensated cirrhosis and 60-70% of patients with decompensated cirrhosis have gastroesophageal varices at the time of diagnosis.

Epidemiology

The frequency of gastroesophageal varices directly correlates with the severity of the liver disease from 40% in Child class A to 85% in Child class C.

Epidemiology

The de novo rate of development of esophageal varices in US patients with chronic liver disease is approximately 8% per year for the first 2 years and 30% by the sixth year. The risk of bleeding from esophageal varices is 30% in the first year after identification.

Bleeding from esophageal varices accounts for approximately 10% of episodes of upper gastrointestinal bleeding.

Epidemiology

Hepatitis B is endemic in the Far East and Southeast Asia, particularly, as well as in South America, North Africa, Egypt, and other countries in the Middle East.

Epidemiology

Schistosomiasis is an important cause of portal hypertension in Egypt, Sudan, southern and sub-Saharan Africa, Southeast Asia, Caribbean, and South America.

Nonalcoholic steatohepatitis (NASH) is becoming a major cause of liver cirrhosis in the United States as hepatitis C is becoming a major cause of liver cirrhosis worldwide.

Sex- and age-related demographics

Liver disease demonstrates a sex predilection, with males making up more than 60% of patients with chronic liver disease and cirrhosis.

Sex- and age-related demographics

Sex- and age-related demographics

Sex- and age-related demographics

In general, alcoholic liver disease and viral hepatitis are the most common causes for esophageal varices in both sexes.

Sex- and age-related demographics

However, veno-occlusive diseases and primary biliary cirrhosis are more common in females; and in females with esophageal varices, alcoholic liver disease, viral hepatitis, veno-occlusive disease, and primary biliary cirrhosis are usually responsible.

In males with esophageal varices, alcoholic liver disease and viral hepatitis are usually the cause.

Sex- and age-related demographics

Portal vein thrombosis and secondary biliary cirrhosis are the most common causes of esophageal varices in children.

Cirrhosis is the most common cause of esophageal varices in adults.

Prognosis

Patients with severe and persistent upper gastrointestinal (GI) hemorrhage (ie, requiring transfusions of >5 U of packed red blood cells) have higher morbidity and mortality rate.

Prognosis

Variceal hemorrhage is the most common complication associated with portal hypertension.

Almost 90% of patients with cirrhosis develop varices, and approximately 30% of varices bleed.

The estimated mortality rate for the first episode of variceal hemorrhage is 30-50%.

Prognosis

Patients with a known diagnosis of esophageal varices have a 30% chance of variceal bleeding within the first year after the diagnosis.

The mortality rate of the bleeding episode depends on the severity of the underlying liver disease.

Prognosis

Prognosis

Patients who have had 1 episode of bleeding from esophageal varices have a 60-80% chance of rebleeding within 1 year after the initial episode; approximately one third of further bleeding episodes are fatal.

Prognosis

The risk of death is maximal during the first few days after the bleeding episode and decreases slowly over the first 6 weeks.

However, despite improvements in therapy, the mortality rate at 6 weeks is remains greater than 20%; this rate is higher when surgical intervention is needed.

Prognosis

Associated abnormalities in the renal, pulmonary, cardiovascular, and immune systems of patients with esophageal varices contribute to 20-65% of deaths in these individuals.

Complications associated with portal hypertension and GI bleeding include the following:

Prognosis

Hepatic encephalopathy Bronchial aspiration, aspiration pneumonia Renal failure Systemic infections, sepsis Spontaneous bacterial peritonitis Ascites Hepatorenal syndrome Bacteremia and/or endotoxemia

Prognosis

Vascular collapse Cardiomyopathy Arrhythmias Hypotension Portal hypertensive gastropathy - This is a

common complication of cirrhosis and portal hypertension, but significant bleeding from this source is relatively uncommon

Prognosis

Other complications include those related to blood transfusion(s) and/or those related to the therapeutic procedures used in the management of bleeding varices.

PrognosisPrognosis in patients with esophageal varices

Patients with a hepatic venous pressure gradient (HVPG) of 20 mm Hg measured 24 hours after the onset of bleeding esophageal varices have a higher 1-year mortality rate.

Prognosis Prognosis in patients with esophageal varices

Other factors that can affect the prognosis of patients with esophageal varices include the following:

Rebleeding

Prognosis Prognosis in patients with esophageal varices

Child classification - Especially the presence of ascites

Active alcohol intake in patients with chronic, alcohol-related liver diseases

Occurrence of complications

Prognosis

Several factors are known to influence the prognosis of esophageal bleeding. These include the following:

The natural course of the disease causing portal hypertension

The severity of the portal hypertension The location and number of the bleeding

varices

Prognosis

The functional status of the liver and the severity of the liver disease - Early rebleeding, within 5 days of admission; occurred in 21% of patients classified as Child-Pugh grade A, 40% of patients classified as grade B, and 63% of patients classified as grade C

Presence of associated systemic disorders Continued alcohol abuse Response to emergency treatment

Patient Education

Educate patients about the benefits and disadvantages of available treatment options.

Alcohol intake should strongly be discouraged, especially in patients with alcoholic cirrhosis. Available resources for alcohol rehabilitation should be provided, along with any prophylaxis for alcohol withdrawal symptoms, when indicated.

Patient Education

Unless contraindicated, all patients with esophageal varices should take beta-blockers to reduce the risk of bleeding.

Patients should also be educated about the adverse effects of beta-blockers and the possible risks of their abrupt discontinuation.

Patient Education

Advise patients who have ascites of the risk of spontaneous bacterial peritonitis during an episode of acute variceal bleeding.